Clinical Trial Update: Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating allogeneic reduced-intensity, haploidentical hematopoietic cell transplantation with GVHD prophylaxis using cyclophosphami…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hematologic Malignancies

Drugs mentioned

• Bortezomib (bortezomib)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Maraviroc (maraviroc)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: HIV, Hematologic Malignancies | Phase 1, Phase 2 | Status: RECRUITING